Reshaping the future of nanopharmaceuticals: Ad iudicium

S. Moein Moghimi*, Dan Peer, Robert Langer

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


We present views on the future development of biologics-based nanopharmaceuticals from a "high risk-high gain" perspective and within the context of personalized therapies. Integrated scientific, commercial, and societal aspects are addressed, and provocative combined realistic biotech, computational, and nanotech approaches for tailor-made engineering of nanopharmaceuticals are discussed.

Original languageEnglish
Pages (from-to)8454-8458
Number of pages5
JournalACS Nano
Issue number11
StatePublished - 22 Nov 2011


Dive into the research topics of 'Reshaping the future of nanopharmaceuticals: Ad iudicium'. Together they form a unique fingerprint.

Cite this